pleiotropic effects of levosimendan on the heart and other organs

Clicks: 85
ID: 210952
2017
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #23 of 26 articles by views in iccea 2004 - 2004 3rd international conference on computational electromagnetics and its applications, proceedings

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract

Levosimendan is a cardiotonic drug with vasodilating properties. The main mechanisms of its action include increased sensitivity of contractile proteins in cardiomyocytes to calcium and its ability to open ATP-dependent potassium channels in the smooth muscles of the vascular walls. In accordance with the recommendations of the European Society of Cardiology, the main indication for drug use is the treatment of acute decompensated chronic heart failure. Since the first use of the drug (15 years ago), a number of additional, pleiotropic effects have been discovered, which not only affect the myocardium (ischemia and remodeling), but might potentiate organoprotective processes “outside” of the cardiovascular system. The experimental and clinical studies have allowed to identify some positive mechanisms beneficially influencing the function of the lungs, kidneys, liver, gastrointestinal tract, central nervous system, as well as the sepsis and inflammation processes. This paper summarizes the existing research and evidence of pleiotropic effects of levosimendan and outlines some potential new areas of its clinical application.

Received 3 April 2017. Accepted 30 May 2017.

Funding: The study did not have sponsorship.
Conflict of interest: Authors declare no conflict of interest.

Reference Key
lomivorotov2017patologipleiotropic Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;V. V. Lomivorotov;V. A. Boboshko
Journal iccea 2004 - 2004 3rd international conference on computational electromagnetics and its applications, proceedings
Year 2017
DOI
10.21688/1681-3472-2017-2-14-28
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.